Bayer announced today that Health Canada has issued a Notice of Compliance (NOC) expanding the indication of LYNKUET (elinzanetant) to include the treatment of moderate to severe vasomotor symptoms (VMS) caused by Adjuvant Endocrine Therapy (AET) related to breast cancer.

With today’s authorisation, LYNKUET becomes the first approved treatment option in Canada for this patient population. This authorisation builds on Health Canada's July 2025 market authorisation of LYNKUET for the treatment of moderate to severe VMS associated with menopause.

Viktoria Friedric, Country President and General Manager, Pharmaceuticals Division, Canada, said, “For women receiving endocrine therapy for breast cancer, hot flashes, night sweats and sleep disruption can have a profound impact on daily life and treatment experience. This market authorisation introduces a new treatment option designed to address moderate to severe vasomotor symptoms (also known as hot flashes and night sweats) in a population with limited therapeutic alternatives.”

In a recent Canadian study, moderate to severe VMS were associated with a 30.2 percent impairment in work productivity and a 35.7 percent impairment in daily activities.